Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
158.14
-0.99 (-0.62%)
At close: Apr 23, 2025, 4:00 PM
158.01
-0.13 (-0.08%)
Pre-market: Apr 24, 2025, 4:09 AM EDT
Ascendis Pharma Revenue
In the year 2024, Ascendis Pharma had annual revenue of 363.64M EUR with 36.34% growth. Ascendis Pharma had revenue of 173.92M in the quarter ending December 31, 2024, with 26.30% growth.
Revenue (ttm)
363.64M EUR
Revenue Growth
+36.34%
P/S Ratio
24.32
Revenue / Employee
357,562 EUR
Employees
1,017
Market Cap
9.51B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ASND News
- 9 days ago - Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory - Seeking Alpha
- 23 days ago - Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia - GlobeNewsWire
- 2 months ago - Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? - Benzinga
- 2 months ago - Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs - GlobeNewsWire
- 2 months ago - Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - GlobeNewsWire